On July 29, 2022 ImmunAdd, a privately held pharmaceutical company developing a fully synthetic, rationally designed, saponin-based small molecule vaccine adjuvant, reported the company attended the BIO International Convention conference in San Diego, California, on June 13-16 (Press release, ImmunAdd, JUL 29, 2022, View Source [SID1234654650]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Founder of ImmunAdd, Pi-Hui Liang, said, "My team and I are delighted to attend the BIO conference in San Diego, where we will show our next generation of saponin adjuvant IA-05 to the world and establish partnerships with companies developing the anti-infective and anti-cancer vaccines. IA-05 is a fully synthetic small molecule which that, in head-to-head preclinical studies against vaccines incorporating several existing adjuvants, including QS-21, demonstrated improved cross-presentation of antigens and well tolerability. Currently, QS-21-incorporated vaccines have shown better protection against virus infection. But QS-21 is less stable, which requires dedicated formulations, such as liposomes, and it is unsustainably sourced."
Professor Shan-Chwen Chang, infectious disease physician, chief advisor of the Central Epidemic Command Center (CECC) of Taiwan, and the executive vice president of National Taiwan University (NTU), said, "Subunit protein-based vaccines are the major player of vaccines, and most of them require adjuvants to make a stronger and longer-lasting immune response. Adjuvants have been used safely for decades in several vaccines. Many important vaccines rely on the new generation of adjuvants to show cross-presentation of antigens and supply economically, yet very few adjuvant can achieve this. It is great to have a new adjuvant that shows better cross-protection."